Metastatic Breast Cancer

Best Practices for Initiating CDK4/6 Inhibitor Therapy in HR+Metastatic Breast Cancer

Arya Mariam Roy, MD

NATALEE and Other Updates for HR+ Early Breast Cancer at SABCS 2025

Komal Jhaveri, MD, FACP, Matthew Kurian, MD

Evolving Treatment Paradigms in Advanced Breast Cancer: Key Trial Updates From SABCS 2025

Karissa Britten, MD, Vaishali Deenadayalan, MD

Key Insights From the NATALEE Trial

Karissa Britten, MD, Matthew Kurian, MD

Comparative Safety of CDK4/6 Inhibitors: Key AEs and Management Approaches

Jasmin Hundal, MD

The Evolving Role of Ribociclib and Optimizing First-Line Treatment in HR+/HER2- Metastatic Breast Cancer

Nerea Lopetegui-Lia, MD